The conventional framing of obesity drugs as weight-loss tools is being fundamentally dismantled. If accumulating trial evidence holds, GLP-1-based therapies may function more like broad metabolic modulators — addressing liver disease, heart failure, kidney decline, sleep apnoea, and even neurodegeneration through mechanisms that operate independently of the scale. That reframing has profound implications for how clinicians select, prescribe, and justify these agents.
This Lancet Diabetes & Endocrinology review synthesises data from randomised controlled trials and high-quality meta-analyses across the current obesity pharmacopeia: older agents including phentermine-topiramate and naltrexone-bupropion, established GLP-1 receptor agonists such as liraglutide and oral and subcutaneous semaglutide, and a newer generation of multiagonist compounds — tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin. Across thirteen-plus comorbid conditions — spanning type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), chronic kidney disease, cardiovascular disease, obstructive sleep apnoea, polycystic ovary syndrome, osteoarthritis, depression, binge-eating disorder, substance use disorders, and neurodegenerative disease — GLP-1-based therapies demonstrated consistent benefit. Critically, the review identifies weight-independent signalling effects, particularly with GLP-1 receptor agonists, as a mechanistically distinct contribution.
This review arrives at a pivotal moment. The SELECT trial (semaglutide, cardiovascular outcomes) and SURMOUNT-OSA (tirzepatide, sleep apnoea) have already shifted clinical thinking beyond glycaemic control, and emerging renal and hepatic trial data are reinforcing the pattern. The weight-independent effects are biologically plausible: GLP-1 receptors are expressed in cardiac tissue, kidney tubules, brain regions governing reward and inflammation, and the gut-liver axis. However, important cautions apply. Many conditions reviewed rely on intermediate endpoints or smaller trials; long-term safety data for newer multiagonists remain limited; and real-world populations may respond differently than tightly controlled trial cohorts. Muscle mass loss associated with rapid weight reduction also warrants monitoring. This is an unusually comprehensive synthesis, and its scope makes it confirmatory for some conditions and hypothesis-generating for others — a meaningful distinction for clinical application.